Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer

Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids

“…Breast cancer, originates as a result of aberrant cell division in the breast, remains the most prevalent malignancy and the leading cause of cancer deaths [ 1 , 2 ]. Currently, standard treatment approaches for breast cancers are surgery accompanied by chemotherapy or radiotherapy, and around 70% of patients with early-stage are curable [ 3 , 4 ]. Thus, chemotherapeutics occupies an important position for the treatment of breast cancer.…”

In Silico Study of a Small Bioactive Molecule Targeting Topoisomerase II and P53-MDM2 Complex in Triple-Negative Breast Cancer

“…Breast cancer is one of the leading causes of death globally owing to its diversity and rapid rate of mutations that lead to change in its characteristics very fast; thus, in several cases common therapeutics could not produce desired outcomes. About 10–15% of all breast cancers are called triple-negative breast cancers (TNBCs) as this breast cancer subtype does not have progesterone and estrogen hormone receptors (PR or ER), and HER2 overexpression too. − This type of cancer cell is generally aggressive as it grows more rapidly. It would be worth mentioning here that only few systemic treatment options are available along with chemotherapy (CT) to treat the TNBCs. − The ‘single drug and single target’ approach does not provide great success.…”

“…About 10–15% of all breast cancers are called triple-negative breast cancers (TNBCs) as this breast cancer subtype does not have progesterone and estrogen hormone receptors (PR or ER), and HER2 overexpression too. − This type of cancer cell is generally aggressive as it grows more rapidly. It would be worth mentioning here that only few systemic treatment options are available along with chemotherapy (CT) to treat the TNBCs. − The ‘single drug and single target’ approach does not provide great success. Moreover, eradication of the resistant cancer cells is a major challenge, where multitarget therapeutics might offer better option as it concurrently inhibits several cellular pathways and thus becomes more lethal toward cancer cells.…”

“…About 10–15% of all breast cancers are called triple-negative breast cancers (TNBCs) as this breast cancer subtype does not have progesterone and estrogen hormone receptors (PR or ER), and HER2 overexpression too. 1 − 3 This type of cancer cell is generally aggressive as it grows more rapidly. It would be worth mentioning here that only few systemic treatment options are available along with chemotherapy (CT) to treat the TNBCs.…”